CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity?
Over recent months, a number of noteworthy case reports and small case series have reported safety and unprecedented efficacy for CD19-targeting Chimeric Antigen Receptor (CAR) T cell therapy in various severe and refractory autoimmune diseases. A new milestone in innovative, cell-based treatment in...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
09 March 2024
|
| In: |
Rheumatology
Year: 2024, Jahrgang: 63, Heft: 9, Pages: 2317-2318 |
| ISSN: | 1462-0332 |
| DOI: | 10.1093/rheumatology/keae144 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/rheumatology/keae144
|
| Verfasserangaben: | Peter Kvacskay and Wolfgang Merkt |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 189822921X | ||
| 003 | DE-627 | ||
| 005 | 20250722163724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240809s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keae144 |2 doi | |
| 035 | |a (DE-627)189822921X | ||
| 035 | |a (DE-599)KXP189822921X | ||
| 035 | |a (OCoLC)1475307138 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kvacskay, Peter |d 1993- |e VerfasserIn |0 (DE-588)1229240853 |0 (DE-627)1751212254 |4 aut | |
| 245 | 1 | 0 | |a CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity? |c Peter Kvacskay and Wolfgang Merkt |
| 264 | 1 | |c 09 March 2024 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.08.2024 | ||
| 520 | |a Over recent months, a number of noteworthy case reports and small case series have reported safety and unprecedented efficacy for CD19-targeting Chimeric Antigen Receptor (CAR) T cell therapy in various severe and refractory autoimmune diseases. A new milestone in innovative, cell-based treatment in systemic autoimmunity is on the horizon. Treatment with CD19-targeting CAR T cells is now an established therapy in haematology, and it is increasingly being suggested for the treatment of various non-malignant diseases [1]. The first use of anti-CD19.CAR T cells in rheumatology was in a patient affected by severe SLE, and significant clinical and serological improvement was observed after the treatment [2]. | ||
| 700 | 1 | |a Merkt, Wolfgang |d 1984- |e VerfasserIn |0 (DE-588)1050296214 |0 (DE-627)783822316 |0 (DE-576)404501125 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology |d Oxford : Oxford Univ. Press, 1999 |g 63(2024), 9, Seite 2317-2318 |h Online-Ressource |w (DE-627)269242813 |w (DE-600)1474143-X |w (DE-576)077883799 |x 1462-0332 |7 nnas |a CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity? |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:9 |g pages:2317-2318 |g extent:2 |a CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity? |
| 856 | 4 | 0 | |u https://doi.org/10.1093/rheumatology/keae144 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240809 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1050296214 |a Merkt, Wolfgang |m 1050296214:Merkt, Wolfgang |d 910000 |d 910100 |e 910000PM1050296214 |e 910100PM1050296214 |k 0/910000/ |k 1/910000/910100/ |p 2 |y j | ||
| 998 | |g 1229240853 |a Kvacskay, Peter |m 1229240853:Kvacskay, Peter |d 910000 |d 910100 |e 910000PK1229240853 |e 910100PK1229240853 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN189822921X |e 4564161180 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"09 March 2024","dateIssuedKey":"2024"}],"id":{"eki":["189822921X"],"doi":["10.1093/rheumatology/keae144"]},"recId":"189822921X","name":{"displayForm":["Peter Kvacskay and Wolfgang Merkt"]},"title":[{"title_sort":"CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity?","title":"CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity?"}],"person":[{"display":"Kvacskay, Peter","family":"Kvacskay","given":"Peter","role":"aut"},{"display":"Merkt, Wolfgang","family":"Merkt","role":"aut","given":"Wolfgang"}],"language":["eng"],"physDesc":[{"extent":"2 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"disp":"CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity?Rheumatology","recId":"269242813","part":{"pages":"2317-2318","volume":"63","extent":"2","text":"63(2024), 9, Seite 2317-2318","year":"2024","issue":"9"},"origin":[{"publisherPlace":"Oxford","dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisher":"Oxford Univ. Press"}],"id":{"issn":["1462-0332"],"zdb":["1474143-X"],"eki":["269242813"]},"pubHistory":["38.1999 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 31. Januar 2017"],"titleAlt":[{"title":"Rheumatology online"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Rheumatology","title_sort":"Rheumatology"}]}],"note":["Gesehen am 09.08.2024"]} | ||
| SRT | |a KVACSKAYPECD19CARTCE0920 | ||